AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Unicycive Plunges 17.65% on FDA Rejection
Generated by AI AgentAinvest Pre-Market Radar
Monday, Jun 30, 2025 7:54 am ET1min read
On June 30, 2025, Unicycive's stock experienced a significant drop of 17.65% in pre-market trading.
Unicycive Therapeutics received a Complete Response Letter from the FDA for its Oxylanthanum Carbonate (OLC) New Drug Application (NDA). The FDA cited deficiencies in third-party manufacturing as the reason for the rejection. The company is actively working with its partners to address these concerns and still anticipates a decision by the PDUFA date of June 28, 2025.
Unicycive's response to the FDA's requests and its confidence in meeting the PDUFA date indicate progress toward resolving the issues, which has been reflected in the stock's recovery.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Esperion Shares Plunge 5.64% as Biopharma Sector Woes, Regulatory Uncertainties Weigh
Dec.15 2025
TSMC Stock Plunges 4.20% Amid Earnings Jitters and Sector-Wide Demand Slowdown
Dec.15 2025
Serve Robotics Surges 5.16% as Trump Admin Boosts Robotics Push, Eyes 10X Revenue by 2026
Dec.12 2025
New Pacific Metals (NPM) Soars 7.98% as Base Metals Market Anticipates Supply/Demand Shifts
Dec.12 2025
Gevo Inc. (GEVO) Surges 6.22% on $26M BioRecro Partnership to Expand Carbon Management Capabilities
Dec.12 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet